WebMar 4, 2024 · Intravenous daratumumab (DARZALEX ®) is a human CD38 monoclonal antibody approved as combination therapy (with bortezomib, melphalan and prednisone) for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (ASCT).The approval was based on results of the phase 3 … WebDec 28, 2024 · The ALCYONE and MAIA phase III trials have demonstrated an overall survival benefit when adding daratumumab to frontline regimens for transplant-ineligible patients with newly diagnosed MM. In transplant-eligible patients, daratumumab-based quadruplet regimens have improved depth of response in the CASSIOPIEA and …
Did you know?
WebSep 26, 2024 · When patients are stratified by high risk, standard risk, low risk, and unfit, Hofmeister suggested, daratumumab would fit for the low-risk and unfit patients. Low-risk patients are defined as having ISS 1 to 2 plus normal lactate dehydrogenase and no translocations for t (4;14), del (17p), or t (4;16). Similarly, unfit patients were those with ... WebJul 24, 2024 · However, the evidence for the effectiveness and safety on hemodialysis patients have not been established, since patients with severe RI were excluded from the pivotal studies (CASTRO trial , ALCYONE trial ). Here, we report a case of refractory MM required dialysis, which was treated safely and effectively with a modified regimen of ...
WebDec 12, 2024 · Subject has non-secretory MM During Screening: Subject received any treatments for MM other than up to 3 cycles of induction therapy per protocol Subject has any of the following laboratory abnormalities: Absolute neutrophil count < 1,000/μL Platelet count < 50,000 mm3 Hemoglobin < 8 g/dL (< 4.9 mmol/L) Serum creatinine clearance < … WebJul 18, 2024 · The ALCYONE trial involved 700 patients and they were randomly assigned to 2 regimens. It was really a European-based regimen. Their standard induction of …
WebApr 8, 2024 · In a pooled analysis of MAIA and ALCYONE trials enrolling NTE patients, a sustained MRD negativity lasting ≥ 12 months was associated with improved PFS compared with MRD negativity lasting less than 12 months or MRD positivity . In a ... Updated results of the randomized phase IV Real MM trial. Blood 2024, 140 (Suppl. S1), 1814–1816. WebDec 13, 2024 · Transplant-Ineligible MM: ALCYONE and MAIA Trials Dec 13, 2024 Keith Stewart, MB, ChB: The 2 big studies that have been performed that have justified the use of daratumumab in a nontransplant-eligible patient are called ALCYONE trial, and they’re called MAIA study.
WebApr 10, 2024 · How to say Alcyone in English? Pronunciation of Alcyone with 6 audio pronunciations, 2 synonyms, 3 meanings, 2 translations, 1 sentence and more for Alcyone.
WebDec 13, 2024 · Transplant-Ineligible MM: ALCYONE and MAIA Trials Dec 13, 2024 Keith Stewart, MB, ChB: The 2 big studies that have been performed that have justified the use … etymology of purdahWebDec 10, 2024 · ALCYONE was a multicentre, randomised, open-label, active-controlled, phase 3 trial that enrolled patients between Feb 9, 2015, and July 14, 2016, at 162 sites in 25 countries across North America, South America, Europe, and the Asia Pacific region. The study design has been published previously. fireworks aerialWebIntroduction: The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China. In the present study, we evaluated the cost … fireworks advertising signsWebThe VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone) trial established fixed-duration treatment with bortezomib, … fireworks aestheticWebA meta-analysis of 3 phase III trials revealed that administering lenalidomide maintenance therapy after ASCT improved PFS and OS outcomes. 12 Additionally, in the phase III TOURMALINE-MM3 trial, maintenance therapy with ixazomib significantly improved PFS outcomes compared with placebo ( P =.002). 13 The CASSIOPEIA trial demonstrated … etymology of pureWebJun 26, 2024 · MM is a plasma cell malignancy, and CD38 has been found to be uniformly highly expressed on MM cells, making it an ideal therapeutic target. 10,13 Much as in … etymology of pupilWebAbout the ALCYONE Trial1. The randomized, open-label, multicenter Phase 3 ALCYONE (MMY3007) study enrolled 706 newly diagnosed patients with multiple myeloma who … fireworks advice for pets